Medlive Technology Yönetim
Yönetim kriter kontrolleri 2/4
We currently do not have sufficient information about the CEO.
Anahtar bilgiler
Liping Tian
İcra Kurulu Başkanı
CN¥4.8m
Toplam tazminat
| CEO maaş yüzdesi | 35.8% |
| CEO görev süresi | 11.6yrs |
| CEO sahipliği | 1.1% |
| Yönetim ortalama görev süresi | Veri yok |
| Yönetim Kurulu ortalama görev süresi | 6.3yrs |
Son yönetim güncellemeleri
Recent updates
Investors Shouldn't Be Too Comfortable With Medlive Technology's (HKG:2192) Earnings
Oct 02
Pinning Down Medlive Technology Co., Ltd.'s (HKG:2192) P/E Is Difficult Right Now
Sep 27Medlive Technology (HKG:2192) Could Be Struggling To Allocate Capital
Jul 04Medlive Technology Co., Ltd.'s (HKG:2192) Business Is Yet to Catch Up With Its Share Price
Apr 08Medlive Technology (HKG:2192) Is Reinvesting At Lower Rates Of Return
Feb 20Are Medlive Technology Co., Ltd. (HKG:2192) Investors Paying Above The Intrinsic Value?
Jan 10Medlive Technology Co., Ltd.'s (HKG:2192) Intrinsic Value Is Potentially 20% Below Its Share Price
Sep 27Medlive Technology (HKG:2192) Is Reinvesting At Lower Rates Of Return
Jul 10Medlive Technology Co., Ltd. (HKG:2192) Shares Slammed 28% But Getting In Cheap Might Be Difficult Regardless
May 11Robust Earnings May Not Tell The Whole Story For Medlive Technology (HKG:2192)
May 02Results: Medlive Technology Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates
Mar 26Here's What's Concerning About Medlive Technology's (HKG:2192) Returns On Capital
Feb 06There Are Reasons To Feel Uneasy About Medlive Technology's (HKG:2192) Returns On Capital
Oct 31Medlive Technology (HKG:2192) Could Be Struggling To Allocate Capital
Jul 14These Analysts Just Made A Massive Downgrade To Their Medlive Technology Co., Ltd. (HKG:2192) EPS Forecasts
Apr 03Is Medlive Technology Co., Ltd. (HKG:2192) Worth HK$9.5 Based On Its Intrinsic Value?
Feb 22CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | CN¥290m |
| Mar 31 2024 | n/a | n/a | CN¥266m |
| Dec 31 2023 | CN¥5m | CN¥2m | CN¥242m |
| Sep 30 2023 | n/a | n/a | CN¥216m |
| Jun 30 2023 | n/a | n/a | CN¥189m |
| Mar 31 2023 | n/a | n/a | CN¥153m |
| Dec 31 2022 | CN¥7m | CN¥2m | CN¥117m |
| Sep 30 2022 | n/a | n/a | CN¥83m |
| Jun 30 2022 | n/a | n/a | CN¥48m |
| Mar 31 2022 | n/a | n/a | CN¥44m |
| Dec 31 2021 | CN¥7m | CN¥1m | CN¥41m |
| Sep 30 2021 | n/a | n/a | CN¥55m |
| Jun 30 2021 | n/a | n/a | CN¥70m |
| Mar 31 2021 | n/a | n/a | CN¥78m |
| Dec 31 2020 | CN¥816k | CN¥816k | CN¥85m |
| Dec 31 2019 | CN¥756k | CN¥756k | CN¥31m |
| Dec 31 2018 | CN¥736k | CN¥736k | CN¥14m |
Tazminat ve Piyasa: Liping's total compensation ($USD682.31K) is above average for companies of similar size in the Hong Kong market ($USD495.13K).
Tazminat ve Kazançlar: Liping's compensation has been consistent with company performance over the past year.
CEO
Liping Tian (57 yo)
11.6yrs
Görev süresi
CN¥4,839,000
Tazminat
Ms. Liping Tian is Chairwoman and Chief Executive Officer of Medlive Technology Co. Ltd. Ms. Tian has been Executive Director of Medlive Technology Co. Ltd since April 2013. She has been the executive dire...
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Chairwoman & CEO | 11.6yrs | CN¥4.84m | 1.1% HK$ 68.9m | |
| President | 10.9yrs | CN¥2.14m | 0.27% HK$ 17.1m | |
| VP, Deputy Head of Medical Information Science Research Unit & Executive Director | 10.9yrs | CN¥2.04m | 0.21% HK$ 13.4m | |
| VP & Executive Director | 6.3yrs | CN¥673.00k | Veri yok | |
| Independent Non-Executive Director | 3.8yrs | CN¥120.00k | Veri yok | |
| Non-Executive Director | 10.9yrs | Veri yok | Veri yok | |
| Independent Non-Executive Director | 3.8yrs | CN¥120.00k | Veri yok | |
| Independent Non-Executive Director | 3.8yrs | CN¥120.00k | Veri yok | |
| Non-Executive Director | 1.6yrs | Veri yok | Veri yok |
6.3yrs
Ortalama Görev Süresi
55yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: 2192's board of directors are considered experienced (6.3 years average tenure).